Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

Prior treatment

• The patients had previously received BTK inhibitors.
• The patients have contraindications to any drug in the combined treatment.

Other illness

• Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
• Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug.

Age

• Pregnant and lactating women, and subjects of childbearing age who do not want to use contraception.

Other

• DLBCL combined with other types of lymphoma. Transformed DLBCL.
• DLBCL with central nervous system invasion.
• Mentally ill persons or persons unable to obtain informed consent.
• The investigators think that the patient is not suitable for the study.

• Subjects fully understand and voluntarily participate in this study and sign informed consent.
• Aged ≥18 years, both male and female.
• Pathologically confirmed CD5-positive DLBCL
• There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
• Eastern Cooperative Oncology Group(ECOG) performance status score of 0-2.
• Expected survival ≥3 months.
• Sufficient bone marrow, liver, and kidney function.